On September 9, 2026, Japan's Central Social Insurance Medical Council (Chuikyo, 中医協) issued its advisory report at the 656th assembly, carrying the draft ministerial ordinance and public notice that revise the Insurance Pharmacy and Pharmacist Treatment Rules under the revised Pharmaceutical and Medical Device Act (PMD Act, 薬機法). The report (答申, tōshin), added as agenda item 6 of the session convened by the Ministry of Health, Labour and Welfare (MHLW), signals that the committee has formally endorsed the implementing legislation that will reshape how insurance pharmacies operate and how pharmacists bill the National Health Insurance (NHI) system.
For regulatory affairs and compliance leads at Japanese insurance pharmacy chains, this is the binding instrument reaching its final committee stage. The advisory report carries the draft ministerial ordinance (省令, shorei) and the draft public notice (告示, kokuji), the delegated legislation that pharmacists at chains such as Ain Pharmaciez, Tsuruha, Welcia, Sugi and Cocokara Fine must conform dispensing and billing to once promulgated. They are not yet law: the tōshin is a committee-stage report, and the next step is MHLW promulgation in the Kanpō Official Gazette.
What did the Chuikyo advisory report actually carry?
The 656th assembly's agenda item 6 is the tōshin, the formal recommendation responding to the consultation (諮問) opened on the same topic at item 4. The report bundles the draft ministerial ordinance and draft public notice that translate the revised PMD Act's pharmacy provisions into operative treatment rules. Under Japan's unitary civil-law hierarchy, the PMD Act is the parent statute enacted by the National Diet, while the treatment rules are ministerial ordinances the MHLW issues to implement it. The Chuikyo endorsement is the committee green light before the MHLW finalises and promulgates the instruments.
The same assembly also moved item 2, a review of NHI coverage of OTC similar drugs (ＯＴＣ類似薬), and item 3, the creation of a new "partial out-of-insurance treatment" (一部保険外療養) category. These are separate but adjacent revisions to the same treatment-rules framework. Pharmacy compliance teams should read the item 6 ordinance against them, because the billing architecture they sit in is being reworked in parallel.
Which insurance pharmacies and pharmacists are in scope?
Every insurance pharmacy (保険薬局) and insurance pharmacist (保険薬剤師) billing the NHI falls in scope. The treatment rules govern dispensing practice, patient counselling, the health-support function that the PMD Act revision elevates, and the reimbursement points attached to each. The stakeholders with the largest conformity exposure are the nationwide dispensing chains, Ain Pharmaciez, Tsuruha, Welcia, Sugi and Cocokara Fine, plus the pharmacist associations that track reimbursement structure. For these operators the material question is not whether to comply but how fast dispensing protocols, pharmacy system billing configurations and pharmacist scope-of-practice training can be realigned to the revised rules once they enter force.
How does the PMD Act revision reshape pharmacy treatment rules?
The revised PMD Act shifts the regulatory emphasis for insurance pharmacies from a dispensing-focused model to a health-support-focused model (健康支援機能). The draft ordinance and notice set out the treatment-rule changes that operationalise that shift, including the conditions under which pharmacists provide health support services and how those services are billed. Because the same assembly opened the partial out-of-insurance treatment category, pharmacy chains should expect billing logic that distinguishes insured treatment from the new out-of-insurance segment, a change with direct reimbursement impact.
The instruments are drafts, not the promulgated text. The MHLW may adjust wording before Kanpō publication, so compliance teams should treat the current PDFs as near-final but verify against the gazetted version when it lands.
When do the revised rules bind, and what should teams do now?
The binding instruments are not yet in force. The tōshin is the committee recommendation; the ordinance and notice become law only when the MHLW promulgates them in the Kanpō, on the effective date their supplementary provisions fix. The regulatory ladder below sets out where this news sits.
| Stage | Instrument | Status as of September 9, 2026 |
|---|---|---|
| Parent statute | Revised PMD Act (Act No. 145 of 1960) | Enacted |
| Committee recommendation | Chuikyo tōshin (agenda item 6) | Issued September 9, 2026 |
| Delegated legislation | Draft ministerial ordinance (省令) and public notice (告示) | Attached to the tōshin, not yet promulgated |
| Promulgation | Kanpō Official Gazette | Pending |
| Enforcement | Effective date set in supplementary provisions | To be confirmed |
Continuous, per-jurisdiction monitoring of the MHLW and Chuikyo surfaces a change like this the moment the assembly agenda updates, before the gazetted text reaches the trade press.
Subscribe to the free newsletter
Next steps for pharmacy compliance teams: confirm whether your dispensing and billing systems can be reconfigured against the revised treatment rules before the ordinance lands; track the Kanpō promulgation date, because that is when conformity obligations crystallise; brief your reimbursement and pharmacist teams on the shift from dispensing-focused to health-support-focused practice and on the new partial out-of-insurance treatment category. Obsidian tracks Japanese pharmacy and NHI treatment-rule developments as they move through Chuikyo into binding law.
